Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing

William W. Hope, Peter A. Warn, Andrew Sharp, Paul Reed, Brian Keevil, Arnold Louie, Thomas J. Walsh, David W. Denning, George L. Drusano

Research output: Contribution to journalArticle

Abstract

Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

Original languageEnglish (US)
Pages (from-to)3760-3762
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume51
Issue number10
DOIs
StatePublished - Oct 2007

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing'. Together they form a unique fingerprint.

  • Cite this